The Role of the GP-TCM Research Association to Modernization and Globalization of Traditional Chinese Medicine

  • Rudolf Bauer
  • De-an Guo
  • Peter Hylands
  • Tai-Ping Fan
  • Qihe Xu


Traditional Chinese Medicine (TCM) is an ancient medical system using experience-based therapies such as acupuncture and herbal medicine, which has been practised for thousands of years in the diagnosis, prevention and treatment of diseases in Asia.


Traditional Chinese Medicine Chinese Herbal Medicine Aristolochic Acid Good Practice Guideline Intersectoral Collaboration 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Tang JL, Liu BY, Ma KW (2008) Traditional Chinese medicine. Lancet 372:1938–1940PubMedCrossRefGoogle Scholar
  2. 2.
    Unschuld PU (1999) The past 1000 years of Chinese medicine. Lancet 354(4):SIV9Google Scholar
  3. 3.
    Scheid V (1999) The globalization of Chinese medicine. Lancet 354(4):SIV10Google Scholar
  4. 4.
    Cai J (1988) Integration of traditional Chinese medicine with western medicine—right or wrong? Soc Sci Med 27:521–529PubMedCrossRefGoogle Scholar
  5. 5.
    Qiu J (2007) China plans to modernize traditional medicine. Nature 446:590–591PubMedCrossRefGoogle Scholar
  6. 6.
    Uzuner H, Fan TP, Dias A, Guo DA, El-Nezami HS, Xu Q (2010) Establishing an EU-China consortium on traditional Chinese medicine research. Chin Med 5:42PubMedCrossRefGoogle Scholar
  7. 7.
    Uzuner H, Bauer R, Fan TP, Guo DA, Dias A, El-Nezami H, Efferth T, Williamson EM, Heinrich M, Robinson N, Hylands PJ, Hendry BM, Cheng YC, Xu Q (2012) Traditional Chinese medicine research in the post-genomic era: good practice, priorities, challenges and opportunities. J Ethnopharmacol 140:458–468PubMedCrossRefGoogle Scholar
  8. 8.
    Sheng-Ji P (2001) Ethnobotanical approaches of traditional medicine studies: some experiences from Asia. Pharm Biol 39(1):74–79PubMedCrossRefGoogle Scholar
  9. 9.
    Qian ZZ, Dan Y, Liu YZ, Peng Y (2010) Pharmacopoeia of the People’s Republic of China (2010 edition): a milestone in development of China’s healthcare. Chin Herb Med 2(2):157–160Google Scholar
  10. 10.
    Bauer R, Franz G (2010) Modern European monographs for quality control of Chinese herbs. Planta Med 76(17):2004–2011PubMedCrossRefGoogle Scholar
  11. 11.
    Zhang B, Peng Y, Zhang Z, Liu H, Qi Y, Liu S, Xiao P (2010) GAP production of TCM herbs in China. Planta Med 76(17):1948–1955PubMedCrossRefGoogle Scholar
  12. 12.
    Heuberger H, Bauer R, Friedl F, Heubl G, Hummelsberger J, Nögel R, Seidenberger R, Torres-Londoño P (2010) Cultivation and breeding of Chinese medicinal plants in Germany. Planta Med 76(17):1956–1962PubMedCrossRefGoogle Scholar
  13. 13.
    Zhao Z, Guo P, Brand E (2012) The formation of daodi medicinal materials. J Ethnopharmacol 140:476–481PubMedCrossRefGoogle Scholar
  14. 14.
    Pferschy-Wenzig E-M, Bauer R (2009) Quality control of Chinese herbal drugs. In: Houghton P, Mukherjee PK (eds) Evaluation of herbal medicinal products: perspectives on quality, safety, and efficacy. Pharmaceutical Press, London, pp 1–502Google Scholar
  15. 15.
    Heubl G (2010) New aspects of DNA-based authentication of Chinese medicinal plants by molecular biological techniques. Planta Med 76(17):1963–1974PubMedCrossRefGoogle Scholar
  16. 16.
    Liang YZ, Xie PS, Chan K (2010) Perspective of chemical fingerprinting of Chinese herbs. Planta Med 76(17):1997–2003PubMedCrossRefGoogle Scholar
  17. 17.
    Sheridan H, Krenn L, Jiang R, Sutherland I, Ignatova S, Marmann A, Liang X, Sendker J (2012) The potential of metabolic fingerprinting as a tool for the modernisation of TCM preparations. J Ethnopharmacol 140:482–491PubMedCrossRefGoogle Scholar
  18. 18.
    Tilton R, Paiva AA, Guan JQ, Marathe R, Jiang Z, van Eyndhoven W, Bjoraker J, Prusoff Z, Wang H, Liu SH, Cheng YC (2010) A comprehensive platform for quality control of botanical drugs (PhytomicsQC): a case study of Huangqin Tang (HQT) and PHY906. Chin Med 5:30PubMedCrossRefGoogle Scholar
  19. 19.
    Zhao ZZ, Liang ZT, Chan K, Lu GH, Lee ELM, Chen HB, Li L (2010) A unique issue in the standardization of Chinese materia medica: processing. Planta Med 76:1975–1986PubMedCrossRefGoogle Scholar
  20. 20.
    Chan K, Shaw D, Simmonds MS, Leon CJ, Xu Q, Lu A, Sutherland I, Ignatova S, Zhu YP, Verpoorte R, Williamson EM, Duez P (2012) Good practice in reviewing and publishing studies on herbal medicine, with special emphasis on traditional Chinese medicine and Chinese materia medica. J Ethnopharmacol 140:469–475PubMedCrossRefGoogle Scholar
  21. 21.
    Wang J (2010) Evidence-based medicine in China. Lancet 375:532–533PubMedCrossRefGoogle Scholar
  22. 22.
    Jiang M, Yang J, Zhang C, Liu B, Chan K, Cao H, Lu A (2010) Clinical studies with traditional Chinese medicine in the past decade and future research and development. Planta Med 76(17):2048–2064PubMedCrossRefGoogle Scholar
  23. 23.
    Normile D (2003) Asian medicine. The new face of traditional Chinese medicine. Science 299:188–190PubMedCrossRefGoogle Scholar
  24. 24.
    Flower A, Witt C, Liu JP, Ulrich-Merzenich G, Yu H, Lewith G (2012) Guidelines for randomised controlled trials investigating Chinese herbal medicine. J Ethnopharmacol 140:550–554PubMedCrossRefGoogle Scholar
  25. 25.
    Jiang M, Lu C, Zhang C, Yang J, Tan Y, Lu A, Chan K (2012) Syndrome differentiation in modern research of traditional Chinese medicine. J Ethnopharmacol 140:634–642PubMedCrossRefGoogle Scholar
  26. 26.
    van der Greef J (2011) Perspective: all systems go. Nature 480:S87PubMedCrossRefGoogle Scholar
  27. 27.
    van der Greef J, Hankemeier T, McBurney RN (2006) Metabolomics-based systems biology and personalized medicine: moving towards n = 1 clinical trials? Pharmacogenomics 7:1087–1094PubMedCrossRefGoogle Scholar
  28. 28.
    Melchart D, Weidenhammer W, Streng A, Reitmayr S, Hoppe A, Ernst E, Linde K (2004) Prospective investigation of adverse effects of acupuncture in 97733 patients. Arch Intern Med 164:104–105PubMedCrossRefGoogle Scholar
  29. 29.
    Witt CM, Streng A, Weidenhammer W, Wagenpfeil S, Brinkhaus B, Willich SN, Melchart D (2007) The impact of patient expectations on outcomes in four randomized controlled trials of acupuncture in patients with chronic pain. Pain 128:264–271PubMedCrossRefGoogle Scholar
  30. 30.
    Berman BM, Lao L, Langenberg P, Lee WL, Gilpin AM, Hochberg MC (2004) Effectiveness of acupuncture as adjunctive therapy in osteoarthritis of the knee: a randomized, controlled trial. Ann Intern Med 141:901–910PubMedGoogle Scholar
  31. 31.
    Haake M, Müller HH, Schade-Brittinger C, Basler HD, Schäfer H, Maier C, Endres HG, Trampisch HJ, Molsberger A (2007) German acupuncture trials (GERAC) for chronic low back pain: randomized, multicenter, blinded, parallel-group trial with 3 groups. Arch Intern Med 167:1892–1898PubMedCrossRefGoogle Scholar
  32. 32.
    Linde K, Streng A, Jürgens S, Hoppe A, Brinkhaus B, Witt C, Wagenpfeil S, Pfaffenrath V, Hammes MG, Weidenhammer W, Willich SN, Melchart D (2005) Acupuncture for patients with migraine: a randomized controlled trial. JAMA 293:2118–2125PubMedCrossRefGoogle Scholar
  33. 33.
    Vickers AJ, Rees RW, Zollman CE, McCarney R, Smith CM, Ellis N, Fisher P, Van Haselen R (2004) Acupuncture for chronic headache in primary care: large, pragmatic, randomised trial. BMJ 328:744PubMedCrossRefGoogle Scholar
  34. 34.
    Jia J, Yu Y, Deng JH, Robinson N, Bovey M, Cui YH, Liu HR, Ding W, Wu HG, Wang XM (2012) A review of omics research in acupuncture: the relevance and future prospects for understanding the nature of meridians and acupoints. J Ethnopharmacol 140:594–603PubMedCrossRefGoogle Scholar
  35. 35.
    Robinson N, Lorenc A, Ding W, Jia J, Bovey M, Wang XM (2012) Exploring practice characteristics and research priorities of practitioners of traditional acupuncture in China and the EU-A survey. J Ethnopharmacol 140:604–613PubMedCrossRefGoogle Scholar
  36. 36.
    van der Greef J, van Wietmarschen H, Schroën J, Wang M, Hankemeier T, Xu G (2010) Systems biology-based diagnostic principles as pillars of the bridge between Chinese and Western medicine. Planta Med 76(17):2036–2047PubMedCrossRefGoogle Scholar
  37. 37.
    Buriani A, Garcia-Bermejo ML, Bosisio E, Xu Q, Li H, Dong X, Simmonds MS, Carrara M, Tejedor N, Lucio-Cazaña J, Hylands PJ (2012) Omic techniques in systems biology approaches to traditional Chinese medicine research: present and future. J Ethnopharmacol 140:535–544PubMedCrossRefGoogle Scholar
  38. 38.
    Zhang A, Sun H, Wang Z, Sun W, Wang P, Wang X (2010) Metabolomics: towards understanding traditional Chinese medicine. Planta Med 76(17):2026–2035PubMedCrossRefGoogle Scholar
  39. 39.
    Tejedor Garcia N, Garcia Bermejo L, Fernandez Martinez AB, Olmos Centenera G, Kumari R, Xu Q, Cheng X, Watson S, Lucio Cazaña FJ (2012) MEDLINE-based assessment of animal studies on Chinese herbal medicine. J Ethnopharmacol 140:545–549PubMedCrossRefGoogle Scholar
  40. 40.
    Barlow DJ, Buriani A, Ehrman T, Bosisio E, Eberini I, Hylands PJ (2012) In-silico studies in Chinese herbal medicines’ research: Evaluation of in silico methodologies and phytochemical data sources, and a review of research to date. J Ethnopharmacol 140:526–534PubMedCrossRefGoogle Scholar
  41. 41.
    Chen ST, Dou J, Temple R, Agarwal R, Wu KM, Walker S (2008) New therapies from old medicines. Nat Biotechnol 26:1077–1083PubMedCrossRefGoogle Scholar
  42. 42.
    Biochemistry Stone R (2008) Lifting the veil on traditional Chinese medicine. Science 319:709–710CrossRefGoogle Scholar
  43. 43.
    Zhang X, Liu Y, Guo Z, Feng J, Dong J, Fu Q, Wang C, Xue X, Xiao Y, Liang X (2012) The herbalome—an attempt to globalize Chinese herbal medicine. Anal Bioanal Chem 402:573–581PubMedCrossRefGoogle Scholar
  44. 44.
    Shaw D (2010) Toxicological risks of Chinese herbs. Planta Med 17:2012–2018CrossRefGoogle Scholar
  45. 45.
    Debelle FD et al (2008) Aristolochic acid nephropathy: a worldwide problem. Kidney Int 74:158–169PubMedCrossRefGoogle Scholar
  46. 46.
    Fu PP, Xia QS, Lin G, Chou MW (2004) Pyrrolizidine alkaloids-genotoxicity, metabolism enzymes, metabolic activation, and mechanisms. Drug Metab Rev 36:1–55PubMedCrossRefGoogle Scholar
  47. 47.
    Tai YT, But PP, Young K, Lau CP (1993) Adverse effects from traditional Chinese medicine. Lancet 341:892PubMedCrossRefGoogle Scholar
  48. 48.
    Fugh-Berman A (2000) Herb-drug interactions. Lancet 355:134–138PubMedCrossRefGoogle Scholar
  49. 49.
    Ouedraogo M, Baudoux T, Stévigny C, Nortier J, Colet JM, Efferth T, Qu F, Zhou J, Chan K, Shaw D, Pelkonen O, Duez P (2012) Review of current and “omics” methods for assessing the toxicity (genotoxicity, teratogenicity and nephrotoxicity) of herbal medicines. J Ethnopharmacol 140:492–512PubMedCrossRefGoogle Scholar
  50. 50.
    Shaw D, Graeme L, Pierre D, Elizabeth W, Kelvin C (2012) Pharmacovigilance of herbal medicine. J Ethnopharmacol 140:513–518PubMedCrossRefGoogle Scholar
  51. 51.
    Zhang L, Yan J, Liu X, Ye Z, Yang X, Meyboom R, Chan K, Shaw D, Duez P (2012) Pharmacovigilance practice and risk control of Traditional Chinese Medicine drugs in China: current status and future perspective. J Ethnopharmacol 140:519–525PubMedCrossRefGoogle Scholar
  52. 52.
    Youns M, Hoheisel JD, Efferth T (2010) Toxicogenomics for the prediction of toxicity related to herbs from traditional Chinese medicine. Planta Med 76(17):2019–2025PubMedCrossRefGoogle Scholar
  53. 53.
    Fan TP, Deal G, Koo HL, Rees D, Sun H, Chen S, Dou JH, Makarov VG, Pozharitskaya ON, Shikov AN, Kim YS, Huang YT, Chang YS, Jia W, Dias A, Wong VC, Chan K (2012) Future development of global regulations of Chinese herbal products. J Ethnopharmacol 140:568–586PubMedCrossRefGoogle Scholar
  54. 54.
    Dobos GJ, Tan L, Cohen MH, McIntyre M, Bauer R, Li X, Bensoussan A (2005) Are national quality standards for traditional Chinese herbal medicine sufficient? Current governmental regulations for traditional Chinese herbal medicine in certain Western countries and China as the Eastern origin country. Complement Ther Med 13(3):183–190PubMedCrossRefGoogle Scholar
  55. 55.
    Pelkonen O, Pasanen M, Lindon JC, Chan K, Zhao L, Deal G, Xu Q, Fan TP (2012) Omics and its potential impact on R&D and regulation of complex herbal products. J Ethnopharmacol 140:587–593PubMedCrossRefGoogle Scholar
  56. 56.
    Vlietinck A, Pieters L, Apers S (2009) Legal requirements for the quality of herbal substances and herbal preparations for the manufacturing of herbal medicinal products in the European union. Planta Med 75(7):683–688PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2013

Authors and Affiliations

  • Rudolf Bauer
    • 1
  • De-an Guo
    • 2
  • Peter Hylands
    • 3
  • Tai-Ping Fan
    • 4
  • Qihe Xu
    • 5
  1. 1.TCM Research Center GrazInstitute of Pharmaceutical Sciences, University of GrazGrazAustria
  2. 2.Shanghai Research Center for TCM ModernizationShanghai Institute of Materia Medica, Chinese Academy of SciencesShanghaiChina
  3. 3.Institute of Pharmaceutical Science, King’s College LondonLondonUK
  4. 4.Department of PharmacologyUniversity of CambridgeCambridgeUK
  5. 5.Department of Renal MedicineKing’s College LondonLondonUK

Personalised recommendations